Vical's Phase 1/2 Trial Data Presented at ASM 2016 Shows Bivalent...

Vical's Phase 1/2 Trial Data Presented at ASM 2016 Shows Bivalent...


Vical Incorporated presented data from the randomized, double-blind, placebo-controlled Phase 1/2 clinical trial of its therapeutic genital herpes vaccine in symptomatic herpes simplex virus type 2 infected patients in an oral late-breaker presentation at the American Society for Microbiology Microbe 2016 meeting held in Boston. The slides presented by Mammen P. "Anza" Mammen, Jr., M.D., Vical's Vice President, Clinical Vaccines, will be accessible on Vical's website.



from Biotech News